SLC5A2 and chronic kidney disease: Second, baseline and follow-up data for medications, in particular the prescription of sodium-glucose cotransporter-2 (SGLT2) inhibitors which dramatically decreases CKD progression, and renal replacement therapy were not collected in the study.